Tamoxifen For Breast Cancer Chemoprevention: Low Uptake by High-Risk Women After Evaluation of a Breast Lump
Open Access
- 1 May 2005
- journal article
- Published by Annals of Family Medicine in Annals of Family Medicine
- Vol. 3 (3) , 242-247
- https://doi.org/10.1370/afm.284
Abstract
PURPOSE The Breast Cancer Prevention Trial (BCPT) published results in 1998 showing that the use of tamoxifen in high-risk women reduced the incidence of invasive breast cancer by 49%. We examined the clinical impact of the BCPT to determine whether high-risk women informed of these results would use tamoxifen for chemoprophylaxis and to investigate the factors influencing this decision.Keywords
This publication has 29 references indexed in Scilit:
- Estimates of the Number of U.S. Women Who Could Benefit From Tamoxifen for Breast Cancer ChemopreventionJNCI Journal of the National Cancer Institute, 2003
- First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trialThe Lancet, 2002
- Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutationsBritish Journal of Cancer, 2002
- Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2JAMA, 2001
- Patient Reluctance Toward Tamoxifen Use for Breast Cancer Primary PreventionAnnals of Surgical Oncology, 2001
- Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE TrialBreast Cancer Research and Treatment, 2001
- Chemoprevention of breast cancerBreast Cancer Research and Treatment, 2000
- Breast cancer prevention: a review of current evidenceCA: A Cancer Journal for Clinicians, 2000
- Tamoxifen prevention of breast cancer: an instance of the fingerpost.JNCI Journal of the National Cancer Institute, 1999
- Validation Studies for Models Projecting the Risk of Invasive and Total Breast Cancer IncidenceJNCI Journal of the National Cancer Institute, 1999